Clinical trials: HTLV-1
Herpesviridae Infection, HTLV-I Infection
Assessment of Patients With Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a disease of the nervous system. The exact cause of MS is unknown, but it is believed to be an autoimmune condition.
- Conditions
- Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis
- Trial name
- NCT00001156
- Where
- United States
- Volunteers
- 1,388 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I Infections
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1
Only 5 to 10% of patients infected with HTLV-1 develop a disease related to infection. The two most serious diseases are adult T-cell leukemia (ATL) and Tropical spastic paraparesis /HTLV-I-associated myelopathy (TSP / HAM).
- Trial name
- HAMIL28B (NCT01754311)
- Where
- 2 sites in Martinique
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University Hospital Center of Martinique
HAM/TSP
Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
Background: HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare, progressive disease. It occurs in some people infected with the HTLV-1 virus.
- Trial name
- NCT04799288
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because…
- Conditions
- T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia, Lymphoma
- Trial name
- NCT06698003
- Testing
- Mogamulizumab
- Where
- 7 sites in United States
- Volunteers
- 134 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HTLV-I-associated Myelopathy
The HAM Infliximab Study
An open-label, non-randomised, uncontrolled, proof-of-concept study of eight patients with 'definite' HTLV-I-associated myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
- Trial name
- HAM06 (NCT00823641)
- Testing
- Infliximab
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
HAM/TSP, HTLV-1 Secondary Myelopathy
Pilates Method in People With HAM/TSP
Individuals with HTLV-1 secondary myelopathy (HAM/TSP) may have motor and sensory alterations, which may result in reduced functional performance and consequent risk of falls.
- Conditions
- HAM/TSP, HTLV-1 Secondary Myelopathy, Balance, Gait Balance
- Trial name
- NCT04830319
- Testing
- Pilates Method, task-oriented training protocol
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Pedreira, Érika, M.D.
Tropical Spastic Paraparesis, HTLV-1
Urological Physical Therapy in HTLV-1 With Urinary Symptoms
Urological physical therapy is described to improve urinary symptoms in patients with myelopathy or neurological dysfunction and to increase the quality of life.
- Trial name
- UROHTLV (NCT01651819)
- Testing
- Urological physical therapy
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
HIV, HTLV-1
Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa
Kinshasa, Democratic Republic of Congo (DRC), is where human immunodeficiency virus type 1 (HIV-1) appears to have most diversified.
- Conditions
- HIV, HTLV-1, Hepatitis C, Chronic
- Trial name
- NCT02439918
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
T-cell Lymphoma, B-Cell Lymphoma
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol.
- Conditions
- T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
- Trial name
- NCT00001582
- Where
- United States
- Volunteers
- 902 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-1
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
This study will examine the use of the humanized Mik-Beta-1 (Hu Mik-(SqrRoot) 1) monoclonal antibody in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- Trial name
- NCT00076843
- Testing
- Hu MiK-Beta-1
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HTLV-I Infections, Tropical Spastic Paraparesis
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
This is a pilot study of intervention in a group of patients with tropical spastic paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus zidovudine in this group of patients.
- Trial name
- NCT02655471
- Testing
- "Raltegravir" and "Zidovudine"
- Where
- Peru
- Volunteers
- 10 people
- Sponsor
- Universidad Peruana Cayetano Heredia
Human T-Lymphoma Virus Type I
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
This study will identify chemical and protein markers in the blood of people who carry the human T-lymphotropic virus type I (HTLV-I), a virus associated with various pathologies, including an increased risk in adults of a rare…
- Trial name
- NCT00339638
- Where
- 5 sites in United States, Jamaica and 1 more
- Volunteers
- 228 people
- Sponsor
- National Cancer Institute (NCI)
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study I (REDS I)
To conduct a multicenter epidemiologic study of the human retroviruses HIV-1, HIV-2, HTLV-I, and HTLV-II in volunteer blood donors from areas of the United States that were reportedly at high and medium or low risk for HIV.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00005278
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HTLV-I Infections, HTLV-II Infections
Dual Algorithm Post Market Clinical Study
The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive…
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03146013
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MP Biomedicals, LLC
HTLV-1
Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus
Testing the effectiveness of an exercise protocol engines sensory performed through a virtual reality platform in individuals infected with HTLV-1
- Trial name
- NCT02877030
- Testing
- Video game
- Where
- Brazil
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pedreira, Érika, M.D.
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
- Trial name
- NCT01418430
- Testing
- CHOP-daclizumab
- Where
- United Kingdom
- Sponsor
- King's College Hospital NHS Trust
Lymphoma
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Antiviral therapy may kill viruses such as HTLV-1 that can cause cancer.
- Trial name
- NCT00041327
- Testing
- filgrastim, recombinant interferon alfa, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- AIDS Malignancy Consortium
Adult T-cell Leukemia-Lymphoma, Peripheral T-cell Lymphoma
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
- Trial name
- NCT01169298
- Testing
- Lenalidomide
- Where
- 6 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Celgene